SHR-1819

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Atopic DermatitisPrurigo Nodularis

127 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

1

Cytosar

Teva

Phase 3

12

Fludara

Sanofi

Phase 3

13

Adtralza

LEO Pharma

Phase 3

164

Amlitelimab

Sanofi

Phase 3

25

Certolizumab

Johnson & Johnson

Phase 3

16

DUPIXENT

Regeneron

Phase 3

17

Jaktinib

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3

48

ICP-332

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

29

VC005

JJiangsu vcare pharmaceutical technology co., LTD

Phase 3

510

Tilrekimig

Pfizer

Phase 3

2Show 31 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Atopic Dermatitis3 trials

A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

Recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT07321951·200 enrolled

A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

Completed·Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT06012812·79 enrolled

A Randomized, Open-Label, Parallel-Group Clinical Study to Evaluate the Bioavailability and Safety of Subcutaneous SHR-1819 Injection Administered Using Different Injection Devices in Healthy Subjects

Completed·Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 1·NCT07264335·160 enrolled

Trial1 trial

A Trial of SHR-1819 in Healthy Subjects

Completed·AAtridia Pty Ltd.·Phase 1·NCT04561128·42 enrolled

Double-blind1 trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects

Completed·Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 1·NCT04772365·52 enrolled

Prurigo Nodularis1 trial

Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis

Recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 2/3·NCT06554509·236 enrolled

Adolescents With Moderate-to-severe Atopic Dermatitis1 trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

Recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 3·NCT07309055·201 enrolled

3 more indications

Moderate to Severe Atopic Dermatitis1 trial

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Moderate to Severe Atopic Dermatitis

Completed·Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 3·NCT06468956·652 enrolled

Seasonal Allergic Rhinitis1 trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis

Completed·Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT07091357·108 enrolled

Children and Adolescents With Moderate-to-severe Atopic Dermatitis1 trial

A Phase Ib/II Study to Investigate the Safety、PK and PD of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis

Completed·Guangdong Hengrui Pharmaceutical Co., Ltd·Preclinical·NCT06713499·51 enrolled

Details

Drug Info

Related News